Metabolic syndrome and in-hospital outcomes among pancreatic cancer patients.


Journal Article

AIMS: Metabolic Syndrome (MetS) is an important etiologic and prognostic factor for pancreatic cancer, but few studies have assessed health outcomes among hospitalized pancreatic cancer patients. We examined the associations between MetS and in-hospital outcomes, i.e. pancreatic resection, post-surgery complications, in-hospital mortality and discharge disposition among hospitalized patients with pancreatic cancer. METHODS: Using the Healthcare Cost and Utilization Project (HCUP) Nationwide Inpatient Sample (NIS) dataset from 2007 to 2011, we obtained data on 47,386 patients hospitalized with a primary diagnosis of pancreatic cancer. Descriptive statistics and multivariable regression models were used to compute estimates, odds ratios and 95% confidence intervals adjusting for age, race/ethnicity, and socioeconomic status. RESULTS: Pancreatic cancer patients with MetS were more likely to undergo pancreatic resection (OR: 1.14, 95% CI: 1.04-1.25) compared to those without MetS. However they were less likely to experience post-surgical complications (OR: 0.90, 95% CI: 0.81-0.99), discharge to a skilled nursing facility (OR: 0.90, 95% CI: 0.83-0.93), and less likely to experience in-hospital mortality (OR: 0.52, 95% CI: 0.44-0.61) compared to those without MetS. CONCLUSION: Hospitalized pancreatic cancer patients with a clinical diagnosis of MetS were more likely to receive pancreatic resection, and had reduced odds of post-surgical complications and in-hospital mortality. If confirmed in future studies, then better understanding of the biological mechanisms underlying this association will be needed, potentially leading to the development of clinical and/or molecular biomarkers to improve early diagnosis of pancreatic cancer and identify patients that may benefit from pancreatic resection.

Full Text

Duke Authors

Cited Authors

  • Raviv, NV; Sakhuja, S; Schlachter, M; Akinyemiju, T

Published Date

  • December 2017

Published In

Volume / Issue

  • 11 Suppl 2 /

Start / End Page

  • S643 - S650

PubMed ID

  • 28506606

Pubmed Central ID

  • 28506606

Electronic International Standard Serial Number (EISSN)

  • 1878-0334

Digital Object Identifier (DOI)

  • 10.1016/j.dsx.2017.04.019


  • eng

Conference Location

  • Netherlands